According to Hongbo Pharmaceutical's announcement, the cumulative deviation value of the company's stock price increase exceeded 30% for three consecutive trading days on August 7, August 10, and August 11, 2026, which is an abnormal fluctuation. After self-inspection and verification with the controlling shareholders and actual controllers, as of the date of disclosure of the announcement, there were no major matters that should have been disclosed but not disclosed, and there have been no major changes in the normal operation of the company. The company reminds investors to pay attention to transaction risks and invest rationally.

According to Hongbo Pharmaceutical's announcement, the cumulative deviation value of the company's stock price increase exceeded 30% for three consecutive trading days on August 7, August 10, and August 11, 2026, which is an abnormal fluctuation. After self-inspection and verification with the controlling shareholders and actual controllers, as of the date of disclosure of the announcement, there were no major matters that should have been disclosed but not disclosed, and there have been no major changes in the normal operation of the company. The company reminds investors to pay attention to transaction risks and invest rationally.